Skip to Main content Skip to Navigation
Journal articles

Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases

Abstract : Dendritic cells are major contributors to inflammatory bone destruction in human through RANKL mediation and could represent a new therapeutic target. Bone-resorbing cells, osteoclasts (OCs), and antigen-presenting cells, dendritic cells (DCs), share several features. They are derived from a common hematopoietic precursor, exhibit phagocytic activities and their functions are dependent upon receptor activator of nuclear factor kB ligand (RANKL). Upon inflammatory conditions, DCs can transdifferentiate toward functional OCs in the presence of RANKL. It has then been assumed that the increase in proinflammatory cytokines could provide a supportive environment for this transdifferentiation. In this review, we emphasize the molecular mechanisms underlying the potential for DCs to give rise to resorbing OCs in the context of bone-destruction-associated diseases upon inflammatory conditions. Whether these mechanisms reveal new strategies for the discovery of therapeutic targets and drugs is discussed extensively.
Complete list of metadata

Cited literature [76 references]  Display  Hide  Download
Contributor : Arnaud Eyraud Connect in order to contact the contributor
Submitted on : Friday, July 20, 2018 - 1:17:28 PM
Last modification on : Thursday, August 4, 2022 - 4:58:15 PM
Long-term archiving on: : Sunday, October 21, 2018 - 7:20:59 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document



Olivier Lapérine, Claudine Blin-Wakkach, Jérôme Guicheux, Sarah Beck-Cormier, Philippe Lesclous. Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases. Drug Discovery Today, Elsevier, 2016, 21 (9), pp.1345 - 1354. ⟨10.1016/j.drudis.2016.04.022⟩. ⟨inserm-01845424⟩



Record views